Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.01.30
Drug efficacy study in NASH mouse model
Today we would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model (Murakami et al., Cells., 2022). In this paper, the authors evaluated the effect of pemafibrate, a selective PPARa modulator, and tofogliflozin, an inhibitor of Na+/glucose-conjugated transport carrier 2, alone and in combination on the progression of…
2025.01.30
Introduction of the paper using NASH model mouse
One of our clients, Kagawa University, has published the results of a study using our non-alcoholic steatohepatitis (NASH) model on the PLOS ONE Journal. The authors demonstrated that ipragliflozin, an oral selective SGLT2 inhibitor, had a therapeutic effect on the NASH mouse model. Ipragliflozin attenuated the development of steatosis, ballooning, inflammation as well as liver…
2025.01.30
Drug Efficacy Studies in NASH Mouse Model_TGF-b neutralizing antibody
Today, we would like to introduce a study published by our client using our STAM™ mouse model (Okrah et al., npj Precision Oncology, 2018). Title: “Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology” KEYWORD: NASH, HCC, TGF-β, T cells In case you are unfamiliar with…
2025.01.30
Clinically correlated adipose tissue in liver disease model
MASH (Metabolic Dysfunction-Associated Steatohepatitis) is the progressive form of MASLD. The multiple parallel hits hypothesis has been recognized as the pathophysiology underlying MASH/NASH, namely, multiple factors such as alterations in adipose tissue and gut microbial functions contribute to the onset and progression of MASH/NASH [Tilg et al, 2021]. The adipose tissue is also…
2025.01.30
Relationship between DAMPs/PAMPs and pathogenesis of STAM mice
Today, we would like to share with you the correlation between our proprietary STAMTM model for NASH-HCC, and DAMPs/PAMPs related factors. One of the factors that cause inflammation and fibrosis is damage-associated molecule patterns (DAMPs), which are released when tissues and cells are damaged. Pathogen-associated molecule patterns (PAMPs) are known to be released by…
2025.01.30
Fibrosis-related factors and pathogenesis of STAM mice
Today, we would like to introduce the correlation between our proprietary STAMTM model and fibrosis-related factors such as HSP47. NASH is a progressive liver disease that differs from simple fatty liver in that it has a risk of developing liver fibrosis and eventually liver cancer. As the later stages of liver fibrosis, including cirrhosis…
2025.01.30
Wnt/β-catenin in STAM: How does it correlate to human liver cancer?
We would like to share with you the HCC-related gene expression data of our proprietary MASH-HCC model (STAMTM). The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection. By virtue of recent advances in treatment methods, the number of patients with HCC caused by these infections is expected…
2025.01.29
Potential MASH biomarker in NASH-HCC model
We would like to introduce the data for a serological marker from our MASH model (STAMTM model). Hepatocellular ballooning is a key finding distinguishing MASH from simple steatosis in terms of MASH diagnosis. CK-18 (cytokeratin 18) is known as one of the promising non-invasive biomarkers and was also recommended at the AASLD-FDA joint workshop…
2025.01.29
Fibrosis markers in the STAM model
We would like to introduce a non-invasive fibrosis marker. Currently, the most reliable method for MASH diagnosis is histological evaluation through liver biopsy. However, various drawbacks of the liver biopsy method, such as sampling error and burden to patients, have spurred the research and development of non-invasive early-diagnosis markers. One of these potential…
2025.01.29
Introduction of DDC-Induced Cholestatic Liver Disease Mouse Model
We would like to introduce mice model of primary sclerosing cholangitis (PSC), as well as 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine (DDC) mice model. PSC PSC is a chronic bile duct disorder characterized by plaque inflammation, fibrosis, and stricture of the bile ducts, which may progress to the terminal stage requiring liver transplantation. Ursodeoxycholic acid is a potent treatment that…
We can help you advance your research.